<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aminolevulinic acid (topical): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aminolevulinic acid (topical): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aminolevulinic acid (topical): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="113612" href="/d/html/113612.html" rel="external">see "Aminolevulinic acid (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50193009"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ameluz;</li>
<li>Levulan Kerastick</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872288"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Levulan Kerastick</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50193012"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Photosensitizing Agent, Topical;</li>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F50193033"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Should only be applied by qualified medical personnel (not intended for application by patients).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bb58f89-580c-47cf-bf9c-e5c96334fe50">Actinic keratosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis:</b> Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Gel (Ameluz): Apply ~1 mm thick to actinic keratosis and to ~5 mm of surrounding skin; application area should not exceed 20 cm<sup>2</sup> and a maximum of 2 g at one time. Cover with a light-blocking occlusive dressing and leave on for 3 hours. After 3 hours of occlusion, remove dressing, wipe off remaining gel, and follow with red light illumination. Lesions that have not completely resolved after 3 months following the initial treatment may be retreated.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution (Levulan Kerastick): Apply to actinic keratoses (<b>not</b> perilesional skin) followed by blue light illumination 3 hours (upper extremity lesions) or 14 to 18 hours (face or scalp lesions) later. Application/treatment may be repeated at a treatment region (once) after 8 weeks; multiple lesions can be treated within a treatment region but multiple treatment regions should not be treated simultaneously.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62238c98-a4cb-42ba-9906-b1164fbba38c">Actinic cheilitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic cheilitis (off-label use):</b> Topical: Apply solution (20%) to lip lesion followed 2 to 3 hours later by photodynamic therapy. Application/treatment may be repeated as necessary once every 4 weeks or until complete clearing, for up to 3 treatment sessions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15552607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15552607'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990380"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987362"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F50193034"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50193025"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Application site scaling (≤87%; severe: ≤22%), burning sensation of skin (≤96%; severe: ≤73%), crusted skin (≤71%; severe: ≤5%, including scabbing), exfoliation of skin (19%), hyperpigmentation (≤73%; severe: 9%), hypopigmentation (≤50%; severe: 4%), local dryness of skin (≤87%; severe: ≤22%), localized vesiculation (≤41%; severe: ≤5%), skin erosion (2% to 14%; severe: 1%), stinging of the skin (≤96%; severe: ≤73%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site discharge (≤41%; severe: ≤5%, including oozing), application site edema (1% to 56%; severe: 4%), application site erythema (35% to 100%; severe: 65%), application site induration (12%), application site irritation (72%), application site pruritus (8% to 34%; severe: 1% to 7%), application site vesicles (12%), local pain (≤92%; severe: ≤30%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (2% to 4%), excoriation of skin (1%), pruritic rash (perilesional: &lt;2%), pustules (1% to 4%), skin blister (&lt;2%), skin pain (1%), skin tenderness (1% to 2%), urticaria (2% to 7%; severe: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Local hemorrhage (1% to 4%), squamous cell carcinoma (2% to 10%), squamous cell carcinoma of skin (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, dysesthesia (2%), headache, hyperalgesia (6%), local discomfort (3%), paresthesia (application site: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eyelid edema</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (2% to &lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, pustular rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Feeling hot, nervousness, pain</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Dermatologic: Skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, skin discoloration (application site)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, temporary amnesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, eye irritation, ocular hyperemia, photophobia</p></div>
<div class="block coi drugH1Div" id="F50192900"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to aminolevulinic acid or any component of the formulation; known allergy/hypersensitivity to porphyrins; known porphyria; hypersensitivity to soybean phosphatidylcholine (Ameluz); cutaneous photosensitivity at wavelengths of 400 to 450 nm (Levulan Kerastick); photodermatoses (Ameluz)</p></div>
<div class="block war drugH1Div" id="F50193023"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity (including anaphylaxis) has been reported with application of gel (Ameluz) prior to photodynamic therapy (PDT). If hypersensitivity occurs, clean area of skin where gel was applied and institute appropriate therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mucous membrane irritation: May cause irritation to mucous membranes; do not apply to mucous membranes; rinse with water if contact occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular injury: Eyelid edema has been observed with topical aminolevulinic acid. Do not apply into eyes; rinse with water if eye contact occurs. Illumination light therapy may result in eye irritation, glare, or injury. During light treatment, patients, health care personnel, and any others present during illumination should wear appropriate eye protection. Avoid staring directly into the light source. Eye exposure to red light must be prevented.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Treatment site will become photosensitive following topical application. Patients should be instructed to avoid exposure to sunlight, bright indoor lights, or tanning beds for 40 hours following application for blue light treatment or for 48 hours following application for red light treatment. Exposure may result in lesion burning, edema, erythema, and/or stinging. Sunscreen will not protect against visible light; head should be covered with light-opaque material or wide-brimmed hat. If unable to return for blue light treatment, continue to avoid sunlight/bright light exposure to treated lesions for at least 40 hours. If unable to perform red light illumination within 3 hours of gel application, protect lesion sites and surrounding skin from sunlight or prolonged intense light (eg, tanning beds, sun lamps) for 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin irritation: Excessive irritation may occur if solution (Levulan Kerastick) is applied under occlusion for &gt;3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transient amnesia: Transient amnestic episodes have been reported with aminolevulinic acid in combination with PDT. Advise patients to report amnesia that occurs after treatment.</p>
<p style="text-indent:0em;">
<b>
<i>Disease-related concerns: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation defects: Has not been tested in individuals with coagulation defects (acquired or inherited). Avoid bleeding during lesion preparation in patients with coagulation defects; bleeding must be controlled prior to application.</p>
<p style="text-indent:0em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitizing agents: Concomitant use of other known photosensitizing agents may increase the degree of photosensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only. Do not apply to eyes or mucous membranes. Application of solution (Levulan Kerastick) should involve lesions on the scalp, face, or upper extremities, although not simultaneously; avoid application to perilesional skin. Should be applied by a qualified health professional.</p></div>
<div class="block foc drugH1Div" id="F50193046"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ameluz: 10% (2 g) [contains isopropyl alcohol, phosphatidylcholine, soy, polysorbate 80, propylene glycol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levulan Kerastick: 20% (1 ea) [contains alcohol, usp, isopropyl alcohol, laureth, polyethylene glycol (macrogol)]</p></div>
<div class="block geq drugH1Div" id="F50193011"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50193048"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Ameluz External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per gram): $207.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Levulan Kerastick External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20% (per each): $471.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872289"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, External, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Levulan Kerastick: 20% (1 ea) [contains alcohol, usp, isopropyl alcohol, laureth, polyethylene glycol (macrogol)]</p></div>
<div class="block adm drugH1Div" id="F50193038"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For topical use only; not for ophthalmic, oral, or intravaginal use. During light treatment, both patients and health care personnel should wear appropriate eye protection.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Gel:</b> Carefully wipe all lesions with an ethanol or isopropanol-soaked cotton pad (to degrease skin) and remove any scaling or crusts prior to application. Gently roughen lesion surfaces (avoid bleeding). Using a gloved fingertip or a spatula, apply gel ~1 mm thick and include ~5 mm of surrounding skin. Application area should not exceed 20 cm<sup>2</sup> and no more than 2 g should be used at one time. May be applied to healthy skin around the lesion(s). Avoid mucous membranes (eyes, nostrils, mouth or ears); maintain a distance of 1 cm from these areas; rinse thoroughly if accidental contact with these areas occurs. Allow gel to dry ~10 minutes before covering with a light-blocking occlusive dressing. After 3 hours, remove dressing and wipe off residual gel. Immediately after removing dressing and residual gel, illuminate the treatment area with red light source. Position lamp 5 to 8 cm from patient's skin. Healthy untreated skin does not need protection during illumination.</p>
<p style="text-indent:-2em;margin-left:2em;">After gel application, protect lesion sites and surrounding skin from sunlight or prolonged intense light (eg, tanning beds, sun lamps) for 2 days. If unable to perform red light illumination within 3 hours of gel application, rinse off gel with saline and water and protect lesion sites and surrounding skin from sunlight or prolonged intense light for 2 days.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Solution:</b> Clean and dry lesion prior to application. Dab lesion gently with wet applicator tip (apply enough to uniformly wet lesion without excess running or dripping). Only apply to affected skin. Do not apply to periorbital area, ocular tissue, or mucosal surfaces. Allow to dry, then reapply to same lesion. Apply to either lesions on scalp, face, or upper extremities, but not to multiple regions simultaneously; lesions on the upper extremities should be occluded with low density polyethylene plastic wrap held in place with elastic net dressing until blue light therapy. Follow application with blue light exposure in 3 hours (upper extremity lesions) or in 14 to 18 hours (face or scalp lesions). Do not wash the application area during the time between application and during photosensitization; prior to blue light therapy, remove occlusive dressing (if applicable) and gently rinse actinic keratosis with water and pat dry. Stinging or burning may occur during blue light treatment. Following blue light treatment, the lesion will temporarily redden, swell and/or scale, which should resolve within 4 weeks after treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">After solution application, advise patient to avoid sunlight/bright light exposure to treated lesions (and wear a wide brimmed hat or other protective apparel) for at least 40 hours after application (burning/stinging sensation may still occur) even if blue light treatment is not performed, interrupted, or is stopped.</p></div>
<div class="block use drugH1Div" id="F50192899"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Gel (Ameluz): Lesion-directed and field-directed topical treatment of mild to moderate actinic keratosis of the face and scalp; to be used in conjunction with photodynamic therapy with narrowband red light illumination (using BF-RhodoLED or RhodoLED XL lamp).</p>
<p style="text-indent:-2em;margin-left:4em;">Solution (Levulan Kerastick): Topical treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities; to be used in conjunction with photodynamic therapy with blue light illumination (using BLU-U blue light).</p></div>
<div class="block off-label drugH1Div" id="F50193016"><span class="drugH1">Use: Off-Label: Adult</span><p>Actinic cheilitis; Basal cell skin cancer, superficial, low risk; Squamous cell skin cancer in situ, low risk (Bowen disease)</p></div>
<div class="block mst drugH1Div" id="F50193007"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aminolevulinic acid (topical) may be confused with aminolevulinic acid (systemic), methyl aminolevulinate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50213630"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50213628"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Photosensitizing Agents: May enhance the photosensitizing effect of Aminolevulinic Acid (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F50193021"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Systemic absorption following topical application is negligible.</p></div>
<div class="block brc drugH1Div" id="F50193022"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if aminolevulinic acid is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Systemic absorption following topical application is negligible.</p></div>
<div class="block pha drugH1Div" id="F50193028"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Aminolevulinic acid is a metabolic precursor of the photosensitizer protoporphyrin IX (PpIX). Photosensitization following local/topical application of aminolevulinic acid occurs through the metabolic conversion to PpIX. When exposed to light of appropriate wavelength and energy, accumulated PpIX produces a photodynamic reaction resulting in local cytotoxicity. Precancerous and cancerous cells exhibit a higher rate of porphyrin induction compared to normal cells.</p></div>
<div class="block phk drugH1Div" id="F50193029"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Peak fluorescence intensity of protoporphyrin IX (PpIX): Actinic keratosis: Solution: 11 hours ± 1 hour; Perilesional skin: 12 hours ± 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean fluorescence clearance half-life of PpIX for lesions: Solution: 30 ± 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Gel: 3 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50213639"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ameluz | Effala</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Levulan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alacare | Ameluz</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Levulan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ameluz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Effala</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Levulan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ameluz | Levulan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alacare</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-15552607">
<a name="15552607"></a>Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic cheilitis. <i>J Drugs Dermatol</i>. 2004;3(5):548-551.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/15552607/pubmed" id="15552607" target="_blank">15552607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ameluz.1">
<a name="Ameluz.1"></a>Ameluz (aminolevulinic acid hydrochloride) [prescribing information]. Woburn, MA: Biofrontera Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17190630">
<a name="17190630"></a>Braathen LR, Szeimies RM, Basset-Seguin N, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. <i>J Am Acad Dermatol</i>. 2007;56(1):125-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/17190630/pubmed" id="17190630" target="_blank">17190630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29331385">
<a name="29331385"></a>Bichakjian C, Armstrong A, Baum C, et al; Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. <i>J Am Acad Dermatol</i>. 2018;78(3):540-559. doi:10.1016/j.jaad.2017.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/29331385/pubmed" id="29331385" target="_blank">29331385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17803601">
<a name="17803601"></a>Kodama M, Watanabe D, Akita Y, Tamada Y, Matsumoto Y. Photodynamic therapy for the treatment of actinic cheilitis. <i>Photodermatol Photoimmunol Photomed</i>. 2007;23(5):209-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/17803601/pubmed" id="17803601" target="_blank">17803601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levulan.1">
<a name="Levulan.1"></a>Levulan Kerastick (aminolevulinic acid hydrochloride) [prescribing information]. Billerica, MA: Pharmalucence, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8949443">
<a name="8949443"></a>Stender IM, Wulf HC. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. <i>Br J Dermatol</i>. 1996;135(3):454-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/8949443/pubmed" id="8949443" target="_blank">8949443</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 113610 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
